ReviewAnnals of intensive care2026
Hypertensive crisis in the critically ill.
Review in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive crises encompass a spectrum of clinical presentations ranging from severe asymptomatic blood pressure (BP) elevation to life-threatening hypertensive emergencies and represent a frequent and challenging situation in the critically ill. While hypertensive urgency, defined as a marked elevation in blood pressure without acute organ damage, can generally be managed in the outpatient setting, hypertensive emergencies require immediate in-hospital management. Hypertensive emergencies are defined by a BP ≥180/110 mmHg associated with acute target-organ damage. Malignant hypertension represents a distinct and severe subset, further characterized by microvascular complications including hypertensive retinopathy and fibrinoid necrosis affecting multiple organs. Initial evaluation is critical to decipher between hypertensive urgency and emergency, with a systematic screening for end-organ damage: cardiovascular system (heart, aorta, and large vessels), central nervous system, retina, and kidneys. The acuity of BP rise, rather than its absolute level alone, largely determines the risk of organ injury, underscoring the importance of a thorough clinical and paraclinical assessment. Once a hypertensive emergency is identified, prompt initiation of intravenous antihypertensive therapy is mandatory. Drug selection, target BP, and the rate of BP reduction must be individualized according to the specific type of end-organ damage. In this narrative review, we summarize current definitions and epidemiology of hypertensive emergencies, detail the clinical approach to initial assessment, and provide an etiology-based overview of management strategies with a focus on intravenous antihypertensive agents and BP targets. Finally, we emphasize the importance of structured long-term follow-up after the acute phase, including etiological workup and optimization of antihypertensive therapy, to prevent recurrence and target-organ failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.